Taken from the annual general meeting in September last year ......

Taken from the annual general meeting in September last year ...

“The other main area of our focus beyond stage one is in Fibrosis diseases
We are particularly interested in pulmonary fibrosis.

While for many fibrosis diseases there are drugs available. In many cases these drugs do not work very well or nave marginal safety profiles.

FAK is known to play and important roll in regulating fibrosis and the data that we have
from our experiments conducted so far, indicate that AMP945 could be effective in both treating and preventing pulmonary fibrosis.
Subject to the results of the phase one trial this is one of the indications that we plan to take AMP945 into more advanced clinical testing.

And it’s certainly an area where the pharmaceutical companies are actively looking to acquire drugs.”


So from today’s announcement ...

“We are very encouraged by the data that is coming in from this Phase 1 clinical study. Our focus is now on completing the trial in a timely manner, fully analysing the data and preparing for future clinical studies in patients with cancer and fibrosis.”

I would say we are getting much closer to the point where pharmaceutical companies are actively looking to acquire drugs.


Then it’s game on ...

.